Astrogen

Based in South Korea, Astrogen specializes in the rapid development and commercialization of innovative treatments for rare neurological disorders, focusing primarily on autism spectrum disorder and cancer therapies. Astrogen, founded in 2017 in Daegu, South Korea, develops treatments for rare neurological disorders. The company is led by CEO Su-kyeong Hwang, who has a history of entrepreneurial ventures. Astrogen raised KRW 2 billion in funding on November 15, 2023, with total funds raised amounting to KRW 2 billion from investor Korea Pharma.

Astrogen Co. , Ltd. specializes in innovative treatments for rare neurological disorders, particularly for autism spectrum disorder (ASD) and cancer. Its flagship product, AST-001, aims to enhance synaptic pruning to improve ASD symptoms and is undergoing Phase 3 trials in South Korea.

Additionally, Astrogen is developing AST-035A, a next-generation cancer therapy targeting glioblastoma and potentially other cancers, with plans for future global market entry. Astrogen's revenue for the most recent year, 2024, was KRW 363,647. 6, with an EBITDA of KRW -5,979,773. 1.

The company generates revenue through partnerships with clinical trial organizations and healthcare institutions, ensuring access to its therapies for patients with ASD and other neurological disorders. Astrogen plans to continue developing AST-001 with an expected completion of Phase 3 trials by early 2024, aiming for commercialization shortly thereafter. The company is targeting expansion into North America and Europe, supported by the recent funding of KRW 2 billion raised from Korea Pharma, which will facilitate scaling its operations and advancing product development.